Humana’s outlook isn’t great, but performance in the fourth quarter was a bit better than expected. Despite the beat, however ...

The dip came after Humana released its 2024 end of year and fourth quarter earnings, which projected an annual profit of ...

Humana forecast annual profit below Wall Street estimates on Tuesday as it anticipates a greater-than-expected decline in its ...

Barclays analyst Andrew Mok raised the firm’s price target on Humana (HUM) to $270 from $255 and keeps an Equal Weight rating on the shares.

RBC Capital analyst Ben Hendrix maintained a Buy rating on Humana (HUM – Research Report) yesterday and set a price target of $283.00. The ...

Humana will make investments to improve its Medicare Advantage Star Ratings, Chief Financial Officer Celeste Mellet said.

Humana shares slid after the health insurer said it expects Medicare Advantage memberships to decline in 2025 before the ...

Humana maintains a healthy balance sheet, in our opinion. Most of its cash and investments ($24 billion as of mid-2024) is held at its subsidiaries, though, and the company aims to hold about $500 ...

Humana posted a $693 million loss in the fourth quarter of 2024, a notable increase from its $541 million loss in the ...

The massive insurer now expects to lose 550,000 Medicare Advantage members — roughly one-tenth its individual MA footprint — ...

Humana's CEO, James Rechtin, emphasized that 2024 adjusted EPS met initial guidance, including investments in Stars and growth, and reaffirmed the 2025 outlook with a continued focus on achieving a 3% ...

Humana backed its adjusted 2025 EPS guidance, which it has said would be "at least in line with 2024 results," or about $15.88. Adjusted EPS is expected to come to $16.25, while FactSet is expecting ...